ADAM17 and cancer: Cleavage of the α3 domain involving the disulphide isomerase ERp5 and ADAM-type proteases such as ADAM10 and ADAM17 (48–50, 67, 68), and thus shedding of the MICA/B from the cancer cell surface, may lead to immune evasion and failure to be recognized by NKG2D-positive cytotoxic cells.